Health-related quality of life in patients with rheumatoid arthritis and in patients with ankylosing spondylitis.

Rheumazentrum Ruhrgebiet, St. Josefs-Krankenhaus, Herne, Germany.
Clinical and experimental rheumatology (Impact Factor: 2.66). 27(4 Suppl 55):S108-11.
Source: PubMed

ABSTRACT In this review the influence of rheumatoid arthritis (RA) and ankylosing spondylitis (AS) on a wide range of health-related quality of life (HRQoL) domains will be described. The domains most frequently studied are pain, functional disability, fatigue and mental problems. In addition, age and socio-economic aspects such as employment and economic status as well as education affect patient-reported HRQoL.Although many studies have assessed the impact on HRQoL of a single disease state, either RA or AS, few studies have focused on a direct comparison between those both diagnostic groups. In general, patients with RA and AS report significant decrements in HRQoL in comparison with the general population. It has been shown that the magnitude of the impairment is similar among both patients group.

  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE.: To describe the long-term physical functioning and its association with somatic comorbidity and comorbid depression in patients with established rheumatoid arthritis (RA). METHODS.: Longitudinal data over a period of eleven years were collected from 882 patients with RA at study inclusion. Patient-reported outcomes were collected in 1997, 1998, 1999, 2002 and 2008. Physical functioning was measured with the Health Assessment Questionnaire and the Physical Component Scale of the Short Form-36 Health Survey. Somatic comorbidity was measured by a questionnaire including 13 chronic diseases. Comorbid depression was measured with the Center for Epidemiologic Depression Scale. We distinguished four groups of patients based on comorbidity at baseline. RESULTS.: 78% of the patients at baseline were women. The mean age was 59.3 (SD 14.8) years and the median disease duration was 5.0 (IQR 2.0-14.0) years. For the total group of patients with RA physical functioning improved over time. Patients with somatic comorbidity, comorbid depression or both, demonstrated worse physical functioning than patients without comorbidity, at all data collection points. Both groups with comorbid depression had the lowest scores. Only patients with both somatic comorbidity and comorbid depression showed significantly less improvement in physical functioning over time. CONCLUSION.: Both somatic comorbidity and comorbid depression were negatively associated with physical functioning during an eleven-year follow-up period. Furthermore, their combination seems to be especially detrimental to physical functioning over time. These results emphasize the need to take somatic comorbidity and comorbid depression into account in the screening and treatment of patients with RA. © 2013 by the American College of Rheumatology.
    Arthritis care & research. 01/2013;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Fatigue is a frequent symptom during ankylosing spondylitis (AS) often under estimated which needs to be measured properly with respect to its intensity by appropriate measures, such as the multidimensional assessment of fatigue (MAF). The aims of this study were to translate into the classic Arabic version of the MAF questionnaire and to validate its use for assessing fatigue in Moroccan patients with AS. The MAF contains 16 items with a global fatigue index (IGF). The MAF was translated and back-translated to arabic, pretested and reviewed by a committee following the Guillemin criteria (J Clin Epidemiol 46:1417-1432, 1993). It was then validate on 110 Moroccan patients with AS. Reliability for the 3-day test-retest was assessed using internal consistency by Cronbach's alpha coefficient and the intra-class correlation coefficient (ICC). External construct validity was assessed by correlation with pain, activity of disease and other keys variable. The reproducibility of the 15 items was satisfactory with a kappa statistics of agreement superior to 0.6. The ICC for IGF score reproducibility was good and reached 0.98 (IC 95%, 0.96-0.99). The internal consistency was at 0.991 with Cronbach's alpha coefficient. The construct validity showed a positive correlation between MAF and the axial (r = 0.34) and peripheral (r = 0.32) visual analogical scale, the Bath ankylosing spondylitis disease activity index (BASDAI) (r = 0.77), the first item of BASDAI (r = 0.85), the functional disability by the Bath ankylosing spondylitis functional index (r = 0.64), the erythrocyte sedimentation rate (r = 0.43) and the C reactive protein (r = 0.30) (for all P < 0.001). There was no statistical correlation between MAF and the other variables. The Arabic version of the MAF has good comprehensibility, internal consistency, reliability and validity for the evaluation of Arabic speaking patients with AS.
    Rheumatology International 12/2011; · 2.21 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To study the factors associated with withdrawal of the and tumor necrosis factor alpha (anti-TNFα) biologics in the treatment of rheumatic diseases. Data from the Hong Kong Biologics Registry were retrieved. The cumulative rates of withdrawal of different biological agents were studied by Kaplan-Meier plot and the incidence of serious adverse events (SAEs) was calculated. Factors associated with the withdrawal of the anti-TNFα agents were studied by Cox regression. Between 2005 and 2013, 2059 courses of biologics were used in 1345 patients. After 3454 patient-years, 1171 (57%) courses were terminated because of clinical inefficacy (38.1%), SAEs (22.3%) and financial reasons (15.9%). The most frequent SAEs (per 100-patient-years) were allergy (2.90), serious infections (1.34), tuberculosis (0.93) and infusion/injection site reaction (0.75). Among the anti-TNFα agents, the cumulative probability of drug withdrawal for either inefficacy or SAEs in 5 years was highest with infliximab (IFX) (64.5%), followed by etanercept (ETN) (44.2%) and adalimumab (ADA) (36.9%). The incidence of serious infections and tuberculosis (per 100 patient-years) for IFX, ETN and ADA users was 1.99, 0.85 and 0.63; and 1.68, 0.43 and 0.85, respectively. Infusion/injection site reaction was highest with IFX (1.38/100 patient-years). Cox regression revealed increasing age, female sex, not having a diagnosis of spondyloarthritis (SpA) and IFX use were significantly associated with drug withdrawal for either inefficacy or SAEs. Rheumatoid arthritis (RA) had the highest hazard ratio for drug withdrawal but SpA was favorable for drug retention, after adjustment for age, sex, disease duration and the choice of anti-TNFα agents. In our registry, the retention rate of the anti-TNFα agents was lowest but the incidence of tuberculosis, serious infections and infusion reaction was highest with IFX. Older female patients with RA and the use of IFX were independently associated with drug withdrawal.
    International Journal of Rheumatic Diseases 12/2013; · 1.65 Impact Factor


Available from